Viking Therapeutics, Inc.
VKTXCIK 0001607678 · Every Form 4 filed by insiders at this issuer.
Filings
6
Latest Mar 27, 2024
Unique insiders
4
Showing
6 of 6
Page 1
Top insiders
Most active reporters at Viking Therapeutics, Inc.
| Name | Roles | Filings |
|---|---|---|
| ZANTE GREG | Officer | 3 |
| FOEHR MATTHEW W | Director | 1 |
| Rowland Charles A Jr | Director | 1 |
| SINGLETON J MATTHEW | Director | 1 |
All filings
6 Form 4 / 4-A filings, newest first
| Filed | Insider | Top transaction | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Mar 27, 2024 | ZANTE GREG Chief Financial Officer | F | 16,610 | $83.34 | $1,384,277 | |
| Mar 4, 2024 | ZANTE GREG Chief Financial Officer | F | 20,093 | $85.22 | $1,712,325 | |
| Jan 4, 2024 | FOEHR MATTHEW W Director | Holdings only | — | — | — | |
| Jan 4, 2024 | Rowland Charles A Jr Director | Holdings only | — | — | — | |
| Jan 4, 2024 | SINGLETON J MATTHEW Director | Holdings only | — | — | — | |
| Jan 4, 2024 | ZANTE GREG Chief Financial Officer | F | 30,889 | $17.40 | $537,469 |
Showing 1–6 of 6
Page 1 of 1
Real-time Form 4 intelligence. Smarter insider tracking.